BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allanore Y, Matucci-Cerinic M, Distler O. Treatment of systemic sclerosis: is there any hope for the future? RMD Open 2016;2:e000260. [PMID: 27486527 DOI: 10.1136/rmdopen-2016-000260] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Cacciapaglia F, Stano S, Fornaro M, Iannone F. Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review. Journal of Scleroderma and Related Disorders. [DOI: 10.1177/23971983221124180] [Reference Citation Analysis]
2 Leong E, Bezuhly M, Marshall JS. Distinct Metalloproteinase Expression and Functions in Systemic Sclerosis and Fibrosis: What We Know and the Potential for Intervention. Front Physiol 2021;12:727451. [PMID: 34512395 DOI: 10.3389/fphys.2021.727451] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
3 Franks JM, Whitfield ML. Insights Into Systemic Sclerosis from Gene Expression Profiling. Curr Treat Options in Rheum 2021;7:208-21. [DOI: 10.1007/s40674-021-00183-0] [Reference Citation Analysis]
4 Khader A, Valiaveetil B, Nalini SD, George B, Sasidharanpillai S, Nazeer MMA, Manikath N. Effect of monthly cyclophosphamide pulses on skin sclerosis in systemic sclerosis. Indian J Dermatol Venereol Leprol 2021;87:728-31. [PMID: 34379952 DOI: 10.25259/IJDVL_796_19] [Reference Citation Analysis]
5 De Pieri A, Korman BD, Jüngel A, Wuertz-Kozak K. Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development. Adv Biol (Weinh) 2021;5:e2000168. [PMID: 33852183 DOI: 10.1002/adbi.202000168] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Stöcker JK, Vonk MC, van den Hoogen FHJ, Nijhuis-van der Sanden MWG, Spierings J, Staal JB, Satink T, van den Ende CHM; ARCH study group. Room for improvement in non-pharmacological systemic sclerosis care? - a cross-sectional online survey of 650 patients. BMC Rheumatol 2020;4:43. [PMID: 32760879 DOI: 10.1186/s41927-020-00142-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA, Obeid M. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol 2020;31:724-44. [PMID: 32194150 DOI: 10.1016/j.annonc.2020.03.285] [Cited by in Crossref: 37] [Cited by in F6Publishing: 65] [Article Influence: 18.5] [Reference Citation Analysis]
8 Nguyen JK, Austin E, Huang A, Mamalis A, Jagdeo J. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch Dermatol Res 2020;312:81-92. [PMID: 31493000 DOI: 10.1007/s00403-019-01972-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
9 Moon S, Bae JM, Park K, Tagkopoulos I, Kim K. Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis. Ann Rheum Dis 2019;78:817-25. [DOI: 10.1136/annrheumdis-2018-214778] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
10 Georgiev T, Stoilov R. Bulgarian rheumatology: science and practice in a cost-constrained environment. Rheumatol Int 2019;39:417-29. [PMID: 30413925 DOI: 10.1007/s00296-018-4202-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
11 Bhattacharyya S, Wang W, Tamaki Z, Shi B, Yeldandi A, Tsukimi Y, Yamasaki M, Varga J. Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis. Front Immunol 2018;9:2434. [PMID: 30405628 DOI: 10.3389/fimmu.2018.02434] [Cited by in Crossref: 21] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
12 Kavian N, Mehlal S, Jeljeli M, Saidu NEB, Nicco C, Cerles O, Chouzenoux S, Cauvet A, Camus C, Ait-Djoudi M, Chéreau C, Kerdine-Römer S, Allanore Y, Batteux F. The Nrf2-Antioxidant Response Element Signaling Pathway Controls Fibrosis and Autoimmunity in Scleroderma. Front Immunol 2018;9:1896. [PMID: 30177933 DOI: 10.3389/fimmu.2018.01896] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 9.3] [Reference Citation Analysis]
13 Cacciatore C, Riviere S, Cohen A, Gatfosse M, Ederhy S, Fain O, Mekinian A. Sclérodermie systémique : efficacité des immunoglobulines intraveineuses pour l’atteinte cardiaque sévère ? La Revue de Médecine Interne 2018;39:594-6. [DOI: 10.1016/j.revmed.2017.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
14 Cidon M, Bansal M, Hartl D. Pulmonary manifestations of rheumatologic diseases. Curr Opin Pediatr 2017;29:311-9. [PMID: 28333695 DOI: 10.1097/MOP.0000000000000496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]